Industry Talks Painful Reality Of Drug Development At NYAS Symposium
This article was originally published in The Pink Sheet Daily
Executive Summary
The 2013 Dr. Paul Janssen Awards honored UCSF’s David Julius for his work in pain, but both science and industry admits pain drug development is suffering due to the complexity and cost of the research.
You may also be interested in...
Huge Market Belies The Long And Difficult Road To Novel Pain Therapies
Since the introduction of the first triptan for aborting migraine in 1992, no truly new class of pain drug – other than off-label use of existing anticonvulsants and antidepressants for neuropathic pain – has reached the market. In fact, the vast majority of pain sufferers today are treated little differently than they would have been a century ago.
Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist
MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30